Loading patent…
AssigneesPfizer Inc., Rinat Neuroscience Corp.
InventorsHong LIANG, Yasmina Noubia ABDICHE, Javier Fernando CHAPARRO RIGGERS, Bruce Charles GOMES, Julie Jia Li HAWKINS, Jaume PONS, Xiayang QIU, Pavel STROP, Yuli WANG
Estimating the term…
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
An isolated antibody that comprises a PCSK9 binding region that competes with, or recognizes a first epitope of PCSK9 that overlaps with a second epitope that is recognized by, a monoclonal antibody selected from the group consisting of 5A10, which is produced by a hybridoma cell line deposited with the American Type Culture Collection and assigned accession number PTA-8986;
An isolated antibody comprising a heavy chain variable region (VH) complementarity determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:59, 60 or 8, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:61 or 9, and a VH CDR3 having the amino acid sequence shown in SEQ ID NO:10, and having one or more conservative amino acid substitutions in CDR1, CDR2, and/or CDR3, wherein the VH CDR1 comprises a substitution at amino acid position 8 of SEQ ID NO:59, the VH CDR2 comprises a substitution at one or more of amino acid positions 3, 4, 5, 6, and 7 of SEQ ID NO:9, and/or a VH CDR3 comprises a substitution at one or both of amino acid positions 7 and 9 of SEQ ID NO:
Dependencies are inferred from the claim text.